LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Accueil・Liste d'Actions・Coherus Oncology Inc

Coherus Oncology Inc

Fermé

SecteurSoins de santé

1.59 -3.64

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.5699999999999998

Max

1.6

Chiffres clés
By Trading Economics
Revenu	-278M -37M
Ventes	-438K 12M
P/E Moyenne du Secteur	3.509 50.102
BPA	-0.25
Marge bénéficiaire	-300.041
Employés	145
EBITDA	7.9M -35M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+400% upside

Dividendes
By Dow Jones
Prochains Résultats	6 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-11M 248M
Ouverture précédente	5.23
Clôture précédente	1.59

Sentiment de l'Actualité

By Acuity

50%

138 / 344 Classement par Healthcare

Coherus Oncology Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 mai 2026, 23:08 UTC

Acquisitions, Fusions, Rachats

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 mai 2026, 23:06 UTC

Acquisitions, Fusions, Rachats

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 mai 2026, 20:53 UTC

Résultats

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 mai 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

29 mai 2026, 20:33 UTC

Market Talk

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 mai 2026, 20:11 UTC

Résultats

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mai 2026, 19:47 UTC

Résultats

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 mai 2026, 19:36 UTC

Market Talk

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 mai 2026, 19:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29 mai 2026, 19:34 UTC

Market Talk

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 mai 2026, 19:22 UTC

Market Talk

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 mai 2026, 19:05 UTC

Acquisitions, Fusions, Rachats

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 mai 2026, 18:19 UTC

Market Talk

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 mai 2026, 18:12 UTC

Acquisitions, Fusions, Rachats

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 mai 2026, 18:11 UTC

Market Talk

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 mai 2026, 18:10 UTC

Market Talk

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 mai 2026, 17:55 UTC

Résultats

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mai 2026, 17:55 UTC

Market Talk

NEAR Protocol Nearly Doubles in May -- Market Talk

29 mai 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 mai 2026, 17:00 UTC

Résultats

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

29 mai 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

29 mai 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29 mai 2026, 16:02 UTC

Market Talk

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 mai 2026, 15:55 UTC

Market Talk

Global Equities Roundup: Market Talk

29 mai 2026, 15:55 UTC

Market Talk

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29 mai 2026, 15:50 UTC

Acquisitions, Fusions, Rachats

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29 mai 2026, 15:50 UTC

Acquisitions, Fusions, Rachats

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29 mai 2026, 15:40 UTC

Market Talk

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29 mai 2026, 15:20 UTC

Market Talk

Canada's Economy Not Looking All That Bright -- Market Talk

Comparaison

Variation de prix

Coherus Oncology Inc prévision

Objectif de Prix

By TipRanks

400% hausse

Prévisions sur 12 Mois

Moyen 8.25 USD 400%

Haut 12 USD

Bas 4 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

Achat

Maintien

Vente

Basé sur 5 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

138 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.